Deinove Announces The Registration Of Its Document De Base With The Autorité Des Marchés Financiers (AMF), The French Market Authority, In The Context Of The Company's Contemplated Initial Public Offering On The Alternext Market Of NYSE Euronext Paris

Paris, March 26 2010 – Deinove, the world's leading specialist in the application of deinococci bacteria to biofuels, green chemistry and antibiotics, announced the registration of its Document de Base with the "Autorité des Marchés Financiers" (AMF) under number I.10-014 on March 25th, 2010. This is a key step towards the company’s contemplated initial public offering on the Alternext market of NYSE Euronext, Paris.

The company is developing breakthrough technologies by leveraging the exceptional biodiversity and robustness of the deinococci (natural bacteria that have been on Earth for over 3 billion years) to elaborate innovative industrial processes – particularly for bioethanol production from biomass and bio-derived waste.

Filing of the Document de Base is the first step towards an initial public offering of Deinove’s shares on NYSE Euronext Paris, which is expected to take place subject to market conditions after approval of the offer prospectus by the AMF.

About Deinove

The biotech company Deinove is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest by exploiting the deinococci's exceptional natural properties. Deinove intends to leverage its proprietary bacterial strains, technologies and processes by outlicensing to industrial partners.

The Paris-based biotech company, which currently has 15 employees, was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Miroslav Radman PhD, one of world’s leading molecular biologists and a member of the French Academy of Science. Professor Radman elucidated and patented the genetic mechanism behind the extraordinary biodiversity and robustness of the bacterium Deinococcus, on which Deinove's innovative strategy is based.

For further information, visit

Back to news